Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people taking Wegovy experience side effects that are mild and mostly digestive — nausea, constipation, a bit of reflux. The rare side effects of Wegovy are a different matter: less common, but worth knowing about before you start, because recognising them quickly is what keeps you safe. Wegovy (semaglutide) is a prescription-only medicine; a prescriber assesses whether it is appropriate for you, and that conversation includes your individual risk profile. This page covers what the clinical evidence and NHS guidance on semaglutide say about the less frequent but more significant reactions reported during treatment.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Before cataloguing the rarer reactions, it helps to understand the framework. Nausea during dose escalation, loose stools in the first couple of weeks, a slightly unsettled stomach after you first pull the pen from the fridge on injection day, these are expected. They are the gut adjusting to a medicine that deliberately slows gastric emptying. What distinguishes a rare serious reaction is usually either its location (chest, back, right-side abdomen), its severity (sudden and intense rather than gradual and dull), or its combination with something else: vomiting alongside severe pain, or swelling alongside difficulty breathing.
Wegovy is a GLP-1 receptor agonist licensed in the UK for weight management; its safety profile has been studied in large clinical trials and continues to be monitored through post-market surveillance. The signals discussed below are drawn from the SmPC, the NHS medicines record, and the MHRA's published communications. They are rare, but they appear in the label for a reason, and dismissing them as impossible would be wrong.
Think of this page as helping you make one simple decision: carry on and monitor, or stop and call for help. If you want a broader overview before reading on, our guide to Wegovy side effects covers the full spectrum from common to rare in one place. The sections below give you the information to make that call clearly.
Pancreatitis (inflammation of the pancreas) is the rare side effect that attracts the most clinical attention for GLP-1 medicines. In January 2026 the MHRA issued a Drug Safety Update reminding prescribers and patients that acute pancreatitis is a known infrequent risk with this class of medicine, and that it can be serious. Rates are low, but the condition is not benign when it does occur.
The warning sign is specific enough to be useful: severe, persistent pain in the upper abdomen that may spread through to the back, often accompanied by nausea or vomiting, and not relieved by ordinary painkillers. This is not the passing queasiness that a lot of people notice after their injection. It is unrelenting and typically worsens rather than settles. If you experience this, stop the injection, do not wait to see if it improves, and seek urgent medical attention, either by calling 999 or going to your nearest emergency department.
People with a personal or family history of pancreatitis, or with high triglyceride levels, should discuss this risk explicitly with their prescriber before starting treatment. It is one of the things a thorough clinical assessment is there to catch. Our wider guide on serious Wegovy side effects covers pancreatitis in more detail alongside other reactions that warrant prompt attention.
Gallbladder disease (including gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis)) appears in the Wegovy SmPC as an uncommon to rare finding, and rapid weight loss of any cause can increase the risk of gallstone formation. Symptoms to look out for include sudden pain in the upper right side of the abdomen, pain that radiates to the right shoulder, fever, or jaundice (yellowing of the skin or whites of the eyes). These warrant same-day contact with a doctor, not a wait-and-see approach.
Serious allergic reactions (anaphylaxis) and severe hypersensitivity are listed as rare in the SmPC. Facial or throat swelling, difficulty swallowing or breathing, a rapid heartbeat, and a sudden drop in blood pressure together constitute an emergency. If any of these occur after an injection, call 999 immediately. Patients sometimes ask what are the side effects of Wegovy when they first notice something unexpected, and understanding where allergic reactions sit in the broader picture can help you respond quickly and confidently.
Heart rate increase is documented in the trials, a small but real average rise in resting pulse was seen with semaglutide. For most people this is clinically insignificant, but anyone with pre-existing arrhythmia or cardiac conditions should flag this for their prescriber. Rare central nervous system effects and injection-site reactions beyond the typical mild redness have also been reported; the NHS semaglutide medicines page lists these in plain language and is worth bookmarking for reference.
A full account of rarer reactions documented across the trial programme is in the complete Wegovy side effects reference on this site.
The practical guide is this. Call 999 or go to A&E for: severe unrelenting abdominal pain (especially if it reaches the back); suspected anaphylaxis; sudden difficulty breathing or throat swelling; symptoms of a serious allergic reaction after an injection.
Contact your prescriber or GP the same day for: pain in the upper right abdomen that persists beyond a few hours; fever alongside abdominal symptoms; yellowing of skin or eyes; a new rash or swelling around injection sites that spreads; any noticeable change in resting heart rate that concerns you; low mood, thoughts of self-harm, or any unusual psychological symptoms (rare but documented in post-market reports for GLP-1 medicines). Our dedicated page on the side effect of Wegovy explains what to tell your GP when you make that call, so you can describe your symptoms clearly and get the right response.
For anything that is unusual but not urgent, our aftercare team is available seven days a week. If you are unsure where your symptom sits, err on the side of contacting a clinician rather than searching for reassurance online.
The MHRA asks that patients and clinicians report suspected side effects through the Yellow Card scheme. Reporting matters, it is how rare signals get detected across a population before they appear in updated guidance. You do not need to be certain a symptom is caused by the medicine; suspicion is enough to file a report.
If you are considering Wegovy and want to understand how your medical history affects your individual risk profile, our prescribers discuss suitability and the full side-effect picture as part of every free consultation. You can check your eligibility to begin that conversation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.